Glenmark Pharmaceuticals Share Price Analyzed
Glenmark Pharmaceuticals saw its stock price rise on November 27th, 2025, driven by good news from the U.S. Food and Drug Administration (FDA). The stock climbed 2% to ₹1,958 per share. This positive movement indicates growing investor confidence in the company’s future.
Key Points
- FDA inspection cleared Glenmark’s North Carolina facility.
- Stock rose 2% to ₹1,958 due to the positive report.
- Commercial manufacturing will restart following the inspection.
- Strong financial results, including a 72% profit increase.
- Total revenue reached ₹6,046.87 crore for the quarter.
- Company market capitalization is ₹55,029.16 crore.
The FDA’s inspection report showed the company’s manufacturing plant in Monroe, North Carolina, passed the inspection. This is a crucial step as the FDA issued a “Voluntary Action Indicated” status, suggesting areas for improvement. Importantly, Glenmark announced they will resume commercial production thanks to this positive outcome.
Glenmark’s stock price was trading at ₹1,950 at 10:49 AM, up 1.5% from the previous day’s close of ₹1,921.30 on the National Stock Exchange (NSE). The overall market, as measured by the NSE Nifty50, was also up, increasing by 87.65 points or 0.33% to 26,292.95.
A total of 0.73 million shares worth ₹143.7 crore were traded on the NSE and BSE during the day. Glenmark’s stock has a wide trading range, fluctuating between ₹2,284.80 and ₹1,275.50 over the past 52 weeks. As of November 27th, the company’s market value stands at a significant ₹55,029.16 crore.
Glenmark reported impressive Q2 results, showcasing a 72.2% jump in profit after tax to ₹610.43 crore. This growth was largely driven by a successful licensing agreement with AbbVie for a new drug, ISB 2001. The company’s total revenue increased by 88.4% to ₹6,046.87 crore, and expenses rose to ₹3,894.98 crore.
"Positive FDA inspections fuel strategic growth and profitability for Glenmark Pharmaceuticals."
